Maze Therapeutics Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines
Reuters
Nov 07
<a href="https://laohu8.com/S/MAZE">Maze Therapeutics</a> Showcases Pipeline Advancements in Precision Kidney and Metabolic Disease Medicines
Maze Therapeutics Inc. has provided an update on its clinical pipeline focused on kidney and metabolic diseases. The company highlighted progress on its lead candidate, MZE829, a precision medicine targeting APOL1-mediated kidney disease (AMKD), which disproportionately affects people of African ancestry. MZE829 is currently enrolling patients in a Phase 2 study, with topline proof-of-concept data expected by the end of the first quarter of 2026. The compound is described as a dual-mechanism APOL1 inhibitor and has demonstrated favorable safety and pharmacokinetic profiles in Phase 1 studies. Additional pipeline programs include MZE782 for chronic kidney disease, with Phase 1 completed and Phase 2 initiation planned for 2026, and a program for phenylketonuria also advancing to Phase 2 next year. Maze Therapeutics reported an expected cash runway extending into 2028. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.